Alto Neuroscience, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Alto Neuroscience completed a $100M registered direct offering (3.78M shares at $26.48/share) in July 2026, bringing pro forma cash to ~$338M with runway through 2030. The company expanded ALTO-207 development to include a Phase 3 monotherapy trial in treatment-resistant depression (PACE-3, initiating H2 2027) alongside the ongoing Phase 2b adjunctive trial (PACE-1, topline H2 2027) and planned Phase 3 adjunctive trial (PACE-2, initiating early 2027). Independent Nature Medicine publication confirmed pramipexole's dopaminergic mechanism with Hedges' g=0.62 effect on anhedonia (p=0.006).
Why this rating
Capital raise represents 181% of company market cap, extending runway significantly and enabling pipeline expansion—material for a $55M company. Monotherapy trial broadens label/addressable market if successful, but clinical risk remains high.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.